Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML
Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.
Related Articles
Optimizing Treatment Sequences Remains Key in CLL/SLL
Real-world data presented at the 2024 ASH Annual Meeting evaluated the efficacy of the most common treatment sequences in CLL/SLL.
Treatment Sequencing Strategies in R/R Multiple Myeloma
A panel of experts on multiple myeloma review patient cases and discuss the treatment of patients with relapsed/refractory disease, highlighting sequencing strategies and clinical trials…
Paying It Forward: The Importance of Mentorship in a Medical Career
Beyond a lengthy list of accomplishments across the leukemia spectrum of treatment, Garcia-Manero holds the importance of mentorship as incredibly dear to his heart and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Phase II trial results on enzalutamide and paclitaxel in LAR-enriched TNBC
Bora Lim, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides a brief overview on the Phase II trial (NCT02276443) of neoadjuvant…
Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia
Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.
Dr Buchbinder on the Potential Role for RP1 Plus Nivolumab in Melanoma After PD-1 Progression
Elizabeth Buchbinder, MD, discusses the implications of the FDA’s decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.
Dr Garmezy on the Rationale for Developing Zelenectide Pevedotin in Urothelial Cancer
Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.
Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma
Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.
Momelotinib Shows Real-World Improvements in Anemia, Symptoms, and Spleen Response in Myelofibrosis
Real-world treatment with momelotinib led to high transfusion independence rates among patients with JAK inhibitor–exposed and –naive myelofibrosis.